3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
Ascendis Pharma (Nasdaq: ASND) will share 3-year clinical data showing sustained improvement in renal function, continued normalization of urine calcium handling, and continued safety and efficacy for adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide).
Data come from the Phase 2 PaTH Forward and Phase 3 PaTHway trials through Year 3 and will be presented at Kidney Week 2025 in Houston on November 6, 2025 (Poster #TH-PO0227; abstract in JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH is a once-daily prodrug of PTH (1-34) designed to deliver physiological PTH levels and is approved as YORVIPATH in the United States, European Union, and European Economic Area for adults with hypoparathyroidism.
Ascendis Pharma (Nasdaq: ASND) condividerà dati clinici di 3 anni che mostrano un miglioramento sostenuto della funzione renale, una continua normalizzazione della gestione del calcio nell'urina e una continua sicurezza ed efficacia per adulti con ipoparatiroidismo trattati con TransCon PTH (palopegteriparatide).
Data provengono dagli studi di fase 2 PaTH Forward e di fase 3 PaTHway fino all’anno 3 e saranno presentati durante la Kidney Week 2025 a Houston il 6 novembre 2025 (Poster #TH-PO0227; abstract in JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH è un prodrug una volta al giorno di PTH (1-34) progettato per fornire livelli fisiologici di PTH ed è approvato come YORVIPATH negli Stati Uniti, nell'Unione Europea e nello Spazio Economico Europeo per adulti con ipoparatiroidismo.
Ascendis Pharma (Nasdaq: ASND) compartirá datos clínicos de 3 años que muestran una mejora sostenida de la función renal, la normalización continua de la gestión del calcio en la orina y la seguridad y eficacia continuas para adultos con hipoparatiroidismo tratados con TransCon PTH (palopegteriparatide).
Los datos provienen de los ensayos de fase 2 PaTH Forward y fase 3 PaTHway hasta el año 3 y se presentarán en la Kidney Week 2025 en Houston el 6 de noviembre de 2025 (Poster #TH-PO0227; resumen en JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH es un profármaco oral diario de PTH (1-34) diseñado para entregar niveles fisiológicos de PTH y está aprobado como YORVIPATH en Estados Unidos, Unión Europea y Espacio Económico Europeo para adultos con hipoparatiroidismo.
Ascendis Pharma (나스닥: ASND) 는 3년 간의 임상 데이터를 공개할 예정이며 신장 기능의 지속적인 개선, 소변 칼슘 처리의 지속적인 정상화 및 성인에서 TransCon PTH (palopegteriparatide)로 치료 시의 안전성과 효과를 지속적으로 보여줄 것입니다.
데이터는 2상 PaTH Forward와 3상 PaTHway 연구에서 3년 차까지 수집되었으며, Kidney Week 2025 가 Houston에서 열리는 2025년 11월 6일에 발표될 예정입니다(포스터 #TH-PO0227; 초록은 JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH 는 PTH(1-34)의 일일 단일 프로드로서 생리학적 PTH 수치를 전달하도록 설계되었으며 미국, EU 및 EEA에서 성인 급갑상샘저하증 치료제로 YORVIPATH로 승인되었습니다.
Ascendis Pharma (NYSE: ASND) partagera des données cliniques sur 3 ans montrant une amélioration soutenue de la fonction rénale, une normalisation continue de la gestion du calcium dans l’urine et la sécurité et l’efficacité continues chez les adultes atteints d’hypoparathyroïdie traités par TransCon PTH (palopegteriparatide).
Les données proviennent des essais de phase 2 PaTH Forward et de phase 3 PaTHway jusqu’à l’année 3 et seront présentées lors de la Kidney Week 2025 à Houston le 6 novembre 2025 (Poster #TH-PO0227; résumé dans JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH est un prodrug quotidien de PTH (1-34) conçu pour délivrer des niveaux physiologiques de PTH et est approuvé comme YORVIPATH aux États‑Unis, dans l’Union européenne et dans l’Espace économique européen pour les adultes atteints d’hypoparathyroïdie.
Ascendis Pharma (Nasdaq: ASND) wird 3-Jahres-Klinikdaten vorlegen, die eine nachhaltige Verbesserung der Nierenfunktion, die fortgesetzte Normalisierung der Kalziumausscheidung im Urin und fortgesetzte Sicherheit und Wirksamkeit bei Erwachsenen mit Hypoparathyreoidismus zeigen, die mit TransCon PTH (palopegteriparatide) behandelt werden.
Die Daten stammen aus der Phase-2-PaTH Forward- und der Phase-3-PaTHway-Studie bis Jahr 3 und werden während der Kidney Week 2025 in Houston am 6. November 2025 vorgestellt (Poster #TH-PO0227; Abstract in JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH ist ein einmal täglich verabreichtes Prodrug von PTH (1-34), das darauf ausgelegt ist, physiologische PTH-Spiegel zu liefern, und ist als YORVIPATH in den USA, der Europäischen Union und dem Europäischen Wirtschaftsraum für Erwachsene mit Hypoparathyreoidismus zugelassen.
Ascendis Pharma (المدرجة في Nasdaq: ASND) ستشارك البيانات السريرية لمدة 3 سنوات التي تُظهر تحسنًا مستمرًا في وظائف الكلى، واستعادة مستمرة لمعالجة الكالسيوم في البول، والأمان والفعالية المستمرة للبالغين المصابين بنقص جار الغدة الدرقية والمعالجين بـ TransCon PTH (palopegteriparatide).
البيانات مستمدة من تجارب المرحلة 2 PaTH Forward والمرحلة 3 PaTHway حتى السنة 3 وستُعرض في أسبوع الكلية 2025 في هيوستن في 6 نوفمبر 2025 (ملصق #TH-PO0227؛ الملخص منشور في JASN 36(10S); DOI 10.1681/ASN.20253yamgex4).
TransCon PTH هو برو دوغ يومي لـ PTH (1-34) مصمم لتوفير مستويات فسيولوجية من PTH ومُعتمد كـ YORVIPATH في الولايات المتحدة والاتحاد الأوروبي والمنطقة الاقتصادية الأوروبية للبالغين المصابين بنقص جارة الغدة الدرقية.
- 3-year clinical data showing sustained renal function improvement
- Normalization of urine calcium maintained through Year 3
- Continued safety and efficacy reported in Phase 2 and Phase 3 trials
- Regulatory approval as YORVIPATH in US, EU, and EEA
- None.
Insights
Three-year trial data show sustained renal benefits, normalized urine calcium handling, and continued safety with TransCon PTH; full details presented at Kidney Week 2025.
What the data show: The trials report sustained improvement in renal function, continued normalization of urine calcium handling, and maintained safety and efficacy through Year 3 with TransCon PTH (palopegteriparatide).
Dependencies and risks: The strength of the claim depends on the specific renal endpoints, magnitude of change, statistical significance, and adverse‑event profile disclosed in the poster and abstract; these details are required to judge clinical and regulatory impact.
What to watch and timing: Refer to the poster presentation #TH-PO0227 on
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9.
| Thursday November 6 10 a.m. – 12 p.m. Convention Center Exhibit Hall | Abstract and Poster #TH-PO0227 Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials Gosmanova, Schwarz,Rejnmark et al Presentation on November 6 by Dr. Elvira Gosmanova The abstract is also available in the Journal of the American Society of Nephrology 36(10S):10.1681/ASN.20253yamgex4, October 2025. | DOI: 10.1681/ASN.20253yamgex4 |
“We are pleased to share this data reinforcing the benefits of long-term treatment with TransCon PTH on renal function,” said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at Ascendis Pharma. “Our goal at this pre-eminant nephrology meeting is to expand awareness and scientific knowledge of TransCon PTH, the kidney’s role in a healthy parathyroid axis, and the importance of delivering physiological levels of PTH for overall kidney health.”
TransCon PTH is a prodrug of PTH (1-34), administered once daily, designed to provide active parathyroid hormone (PTH) within the physiological range for 24 hours/day. TransCon PTH is approved as YORVIPATH® in the United States, European Union, and European Economic Area as a treatment for adults with hypoparathyroidism.
About Hypoparathyroidism
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ plan to present TransCon PTH data during Kidney Week 2025, (ii) Ascendis’ goal to expand awareness of TransCon PTH as an important treatment option, (iii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (iv) Ascendis’ application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. © November 2025 Ascendis Pharma A/S.
| Investor Contacts: Chad Fugere Ascendis Pharma ir@ascendispharma.com Patti Bank ICR Healthcare +1 (415) 513-1284 patti.bank@icrhealthcare.com | Media Contact: Melinda Baker Ascendis Pharma media@ascendispharma.com |
FAQ
When and where will Ascendis Pharma (ASND) present the 3-year TransCon PTH data?
What do the Year 3 PaTH Forward and PaTHway results say about TransCon PTH for ASND?
How is TransCon PTH (palopegteriparatide) administered and what is its mechanism?
Is TransCon PTH approved for adults with hypoparathyroidism?
Where can I find the abstract and DOI for the ASND TransCon PTH Kidney Week presentation?
What implications could the Year 3 renal data have for ASND investors?
